Hajir Ibraheim

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor-induced colitis.

Impact of concurrent colonic CMV infection on clinical outcomes in immune checkpoint inhibitor-induced colitis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 11, 2026

Decoding cytokine networks in ulcerative colitis to identify pathogenic mechanisms and therapeutic targets.

Decoding cytokine networks in ulcerative colitis to identify pathogenic mechanisms and therapeutic targets.

Journal: Science signaling

Published: February 03, 2026

The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy.

The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy.

Journal: Best practice & research. Clinical gastroenterology

Published: June 04, 2024

Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.

Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.

Journal: Journal of Crohn's & colitis

Published: November 09, 2023

Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients.

Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients.

Journal: Gastrointestinal endoscopy

Published: October 10, 2023

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Journal: EClinicalMedicine

Published: July 13, 2023

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis.

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis.

Journal: Journal for immunotherapy of cancer

Published: August 26, 2022

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.

Journal: The lancet. Gastroenterology & hepatology

Published: July 23, 2022

The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.

The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.

Journal: EBioMedicine

Published: June 16, 2022

Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis.

Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23/IFNγ axis.

Journal: Nature communications

Published: January 11, 2022

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.

Journal: The lancet. Gastroenterology & hepatology

Published: December 17, 2021

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.

Journal: Journal of Crohn's & colitis

Published: September 02, 2021

Showing 1-12 of 25

Last Updated: 09/26/2026